|
Angelman Syndrome
|
0.170 |
Biomarker
|
disease |
BEFREE |
Mice deficient for maternal Ube3a (AS mice) exhibit various behavioral features of AS including cognitive and motor deficits although the underlying molecular mechanism is poorly understood.
|
30814928 |
2019 |
|
Angelman Syndrome
|
0.170 |
PosttranslationalModification
|
disease |
BEFREE |
This study tested the hypothesis that by increasing the methylation of the UBE3A-antisense transcript in Angelman syndrome to promote expression of the silenced paternal UBE3A gene we may ameliorate the clinical phenotypes of AS.
|
31640736 |
2019 |
|
Angelman Syndrome
|
0.170 |
Biomarker
|
disease |
BEFREE |
Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by a loss of the maternally-inherited UBE3A; the paternal UBE3A is silenced in neurons by a mechanism involving an antisense transcript (UBE3A-AS) at the unmethylated paternal locus.
|
27860204 |
2016 |
|
Angelman Syndrome
|
0.170 |
GeneticVariation
|
disease |
BEFREE |
The PWS imprinting control region is the promoter for a one megabase paternal transcript encoding the ubiquitous protein-coding Snrpn gene and multiple neuron-specific noncoding RNAs, including the PWS-related Snord116 repetitive locus of small nucleolar RNAs and host genes, and the antisense transcript to AS-causing ubiquitin ligase encoding Ube3a (Ube3a-ATS).
|
23918391 |
2013 |
|
Angelman Syndrome
|
0.170 |
Biomarker
|
disease |
BEFREE |
These studies demonstrate the feasibility and utility of unsilencing the paternal copy of Ube3a via targeting Ube3a-ATS as a treatment for Angelman syndrome.
|
24385930 |
2013 |
|
Angelman Syndrome
|
0.170 |
AlteredExpression
|
disease |
BEFREE |
The mice showed partial activation of paternal Ube3a, with decreased expression of Ube3a-ATS but not any imprinting defects in the Prader-Willi syndrome/Angelman syndrome region.
|
22493002 |
2012 |
|
Angelman Syndrome
|
0.170 |
AlteredExpression
|
disease |
BEFREE |
This maternal imprinting defect results in expression of maternal Ube3a-as and repression of Ube3a in cis, providing evidence that Ube3a is regulated by its antisense and creating the first reported mouse model for AS imprinting defects.
|
16368707 |
2006 |
|
Tumor Cell Invasion
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of SNHG14 inhibited cell growth, induced cell apoptosis, suppressed migration and invasion by inhibiting epithelial-mesenchymal transition process.
|
31692034 |
2020 |
|
Tumor Cell Invasion
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
In vitro experiments showed that higher expression of SNHG14 led to higher cell proliferation, migration and invasion, while miR-186 significantly inhibited these tumor phenotypes.
|
31704614 |
2020 |
|
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
SNHG14 contributed to cell proliferation, migration and invasion, while suppressed apoptosis in CRC cells by targeting miR-944/KRAS axis through PI3K/AKT pathway, representing novel biomarkers for CRC therapy.
|
31799655 |
2019 |
|
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
After SNHG14 was silenced in ovarian cancer cells, cell proliferation, migration, and invasion were remarkably inhibited.
|
31173283 |
2019 |
|
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Moreover, cell migration and invasion were significantly attenuated via the inhibition of SNHG14, while enhanced via the SNHG14 overexpression.
|
31841176 |
2019 |
|
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Our study uncovers a new oncogene in BC and suggests that SNHG14 could enhance BC cell proliferation and invasion via sponging miR-193a-3p, which provided a novel therapeutic target for BC patients.
|
30964172 |
2019 |
|
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
The long non-coding RNA SNHG14 inhibits cell proliferation and invasion and promotes apoptosis by sponging miR-92a-3p in glioma.
|
29552296 |
2018 |
|
Tumor Cell Invasion
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
Functionally, enhanced expression of lncRNA SNHG14 promoted cell migration and invasion through promoting N-WASP protein level.
|
29312804 |
2017 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Consequently, SNHG14 exhibited low expression in CRC tissues and involved in CRC progression and metastasis by competing for miR-92b-3p, and SNHG14 could be used as a valuable biomarker and therapeutic target for CRC.
|
31692034 |
2020 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In this research, lncRNA SNHG14 was studied to identify how it functioned in the development and metastasis of BC.
|
30964172 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Long noncoding RNA SNHG14 promotes ovarian cancer cell proliferation and metastasis via sponging miR-219a-5p.
|
31173283 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
It has been reported that long non-coding RNA SNHG14 promotes cell proliferation and metastasis in multiple cancers.
|
30611620 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In this research, lncRNA SNHG14 was studied to identify its role in the metastasis of ovarian cancer.
|
31841176 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
High expression of SNHG14 was associated with poor tumour differentiation, advanced TNM stage and nodal metastasis.
|
31513352 |
2019 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Consequently, SNHG14 exhibited low expression in CRC tissues and involved in CRC progression and metastasis by competing for miR-92b-3p, and SNHG14 could be used as a valuable biomarker and therapeutic target for CRC.
|
31692034 |
2020 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
However, there is no study regarding the role of SNHG14 in CRC research.
|
31704614 |
2020 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> The extracellular <i>lncRNA SNHG14-</i> hsa-miR-3940-5p - <i>NAP1L2</i> mRNA may aid in CRC management.
|
31397210 |
2019 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Besides, SNHG14 contributed to CRC cell proliferation, motility and EMT in vitro, and inhibition of it confined CRC tumor growth and liver metastasis in vivo.
|
31273190 |
2019 |